Los Angeles Capital Management LLC Invests $9.07 Million in Inspire Medical Systems, Inc. (NYSE:INSP)

Los Angeles Capital Management LLC bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 42,979 shares of the company’s stock, valued at approximately $9,071,000. Los Angeles Capital Management LLC owned approximately 0.14% of Inspire Medical Systems as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in shares of Inspire Medical Systems by 98.9% during the 1st quarter. Russell Investments Group Ltd. now owns 31,933 shares of the company’s stock worth $6,859,000 after buying an additional 15,877 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Inspire Medical Systems by 51.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company’s stock valued at $98,754,000 after acquiring an additional 156,893 shares during the last quarter. Tidal Investments LLC acquired a new position in Inspire Medical Systems in the first quarter valued at $1,151,000. AQR Capital Management LLC grew its holdings in shares of Inspire Medical Systems by 152.7% during the second quarter. AQR Capital Management LLC now owns 231,845 shares of the company’s stock worth $31,028,000 after purchasing an additional 140,090 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its position in shares of Inspire Medical Systems by 27.1% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 40,501 shares of the company’s stock worth $8,699,000 after purchasing an additional 8,625 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on INSP shares. Morgan Stanley dropped their price target on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research note on Monday, July 15th. Robert W. Baird upped their price target on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Stifel Nicolaus reissued a “hold” rating and set a $200.00 price objective (up from $170.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. KeyCorp lowered their price target on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Finally, Wells Fargo & Company lifted their target price on Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems currently has an average rating of “Moderate Buy” and a consensus price target of $227.75.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $202.04 on Tuesday. The company has a market capitalization of $6.06 billion, a PE ratio of 188.82 and a beta of 1.36. The stock has a fifty day moving average of $202.62 and a two-hundred day moving average of $179.12. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $257.40.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, November 4th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.54. The business had revenue of $203.20 million for the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The business’s quarterly revenue was up 32.6% on a year-over-year basis. During the same period last year, the company posted ($0.29) EPS. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 1.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $188.55, for a total value of $916,541.55. Following the completion of the transaction, the insider now owns 3,056 shares in the company, valued at $576,208.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $188.55, for a total transaction of $916,541.55. Following the sale, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,692 shares of company stock worth $1,099,207 over the last ninety days. 4.10% of the stock is owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.